The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

Background: The Gustave Roussy Immune (GRIm)-Score takes into account neutrophil-to-lymphocyte ratio (NLR), serum albumin concentration and lactate dehydrogenase (LDH) and its prognostic value has been investigated in patients treated with immune check-point inhibitors (ICIs). To further assess the...

Full description

Bibliographic Details
Main Authors: Edoardo Lenci, Luca Cantini, Federica Pecci, Valeria Cognigni, Veronica Agostinelli, Giulia Mentrasti, Alessio Lupi, Nicoletta Ranallo, Francesco Paoloni, Silvia Rinaldi, Linda Nicolardi, Andrea Caglio, Sophie Aerts, Alessio Cortellini, Corrado Ficorella, Rita Chiari, Massimo Di Maio, Anne-Marie C. Dingemans, Joachim G. J. V. Aerts, Rossana Berardi
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Clinical Medicine
Subjects:
GRIm-Score
immunotherapy
first-line
NSCLC
pembrolizumab
Online Access:https://www.mdpi.com/2077-0383/10/5/1005

Internet

https://www.mdpi.com/2077-0383/10/5/1005

Similar Items